AGP Executive Report
Last update: 9 hours agoObesity Drug Race: Eli Lilly escalated the fight for obesity care with late-stage TRIUMPH-1 data for retatrutide, showing up to 28.3% average weight loss at 80 weeks (and 45.3% of patients hitting at least 30% loss), tightening pressure on GLP-1 leaders. Regulatory Crackdown: South Africa’s Sahpra and Pharmacy Council seized unregistered injectable GLP-1 products tied to compounding claims, as demand for weight-loss drugs keeps outpacing oversight. Ebola Watch: A suspected Ebola patient in the Netherlands was cleared after negative blood tests, while DR Congo’s outbreak continues to expand. Workplace Safety: UK HSE guidance reiterates there’s no single maximum indoor temperature to stop work, but employers must keep conditions “reasonable” and include heat in risk assessments. Healthcare Business: KPJ Healthcare reported Q1 profit up 22% amid integration efforts, while Kazakhstan approved a major biopharma complex aimed at cutting medicine import dependence. Cancer Care: Real-world monarchE data suggest 75% persistence at 6 months for adjuvant abemaciclib, with discontinuation often driven by adverse events.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result.
Perspectify News
![<![CDATA[What Kinds of Disruption are GLP-1s Expected to Face]]>](https://cdn.sanity.io/images/0vv8moc6/pharmexec/00ab79e7232cedb459de3feda06000401ad87b9e-1280x720.jpg)
